Nova Leap Health Corp.

Unaudited Condensed Interim Consolidated Financial Statements
For the three and six months ended June 30, 2026 and 2025

(United States dollars)

Nova Leap Health Corp.

Unaudited Condensed Interim Consolidated Statements of Financial Position

(United States dollars)

As at	June 30, 2026 $	December 31, 2025 $
ASSETS		
Current assets		
Cash and cash equivalents	**1,441,635**	1,492,925
Accounts receivable	**2,011,357**	1,837,001
Prepaid expenses	**416,561**	261,452
Total current assets	**3,869,553**	3,591,378
Non-current assets		
Property and equipment	**991,677**	908,252
Intangible assets	**999,877**	550,639
Goodwill	**18,962,055**	17,056,993
Deferred income tax asset	**972,815**	1,374,084
Total non-current assets	**21,926,424**	19,889,968
TOTAL ASSETS	**25,795,977**	23,481,346
LIABILITIES		
Current liabilities		
Accounts payable and accrued liabilities	**1,881,041**	1,469,705
Client deposits payable	**42,984**	38,118
Demand loans (note 4)	**3,041,221**	1,786,887
Promissory notes (note 5)	**173,845**	125,899
Lease liability	**371,895**	305,575
Total current liabilities	**5,510,986**	3,726,184
Non-current liabilities		
Promissory notes (note 5)	**227,845**	94,248
Lease liability	**639,256**	618,897
Total non-current liabilities	**867,101**	713,145
TOTAL LIABILITIES	**6,378,087**	4,439,329
SHAREHOLDERS' EQUITY		
Share capital (note 6)	**19,104,212**	19,104,212
Contributed surplus	**2,459,218**	2,416,565
Accumulated other comprehensive loss	**(2,061,245)**	(1,419,901)
Deficit	**(84,295)**	(1,058,859)
TOTAL SHAREHOLDERS' EQUITY	**19,417,890**	19,042,017
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	**25,795,977**	23,481,346

The accompanying notes form an integral part of these unaudited condensed interim consolidated financial statements.

Approved on behalf of the Board of Directors

"Michael O'Keefe"
(signed) Director

"Chris Dobbin"
(signed) Director

Nova Leap Health Corp.

Unaudited Condensed Interim Consolidated Statements of Income (Loss) and Comprehensive Income

(United States dollars)

For the	Three months ended June 30 2026 $	2025 $	Six months ended June 30 2026 $	2025 $
Revenues				
Service revenues	**9,393,302**	8,021,072	**17,245,196**	15,114,696
Operating expenses				
Cost of services	**5,606,840**	4,797,200	**10,326,484**	9,124,094
	3,786,462	3,223,872	**6,918,712**	5,990,602
Corporate and administrative expenses				
Head office and operations management	**2,089,669**	1,917,219	**4,105,110**	3,756,364
General & administrative	**741,957**	728,746	**1,397,458**	1,367,271
Amortization and depreciation	**178,763**	208,890	**327,582**	405,643
Stock-based compensation	**21,406**	18,578	**42,653**	35,733
	3,031,795	2,873,433	**5,872,803**	5,565,011
Income from operating activities	**754,667**	350,439	**1,045,909**	425,591
Other income (expenses)				
Foreign exchange gain (loss)	**251,103**	(799,746)	**496,922**	(816,453)
Finance expense	**(97,754)**	(106,632)	**(176,158)**	(187,734)
Acquisition related expenses	**(25,131)**	(27,435)	**(28,655)**	(76,421)
Other income	**-**	4,873	**-**	-
	128,218	(928,940)	**292,109**	(1,080,608)
Income (Loss) before income taxes	**882,885**	(578,501)	**1,338,018**	(655,017)
Income taxes				
Deferred income tax expense (recovery)	**152,542**	(85,368)	**223,693**	(130,769)
Current income tax expense (recovery)	**80,366**	(9,125)	**139,761**	38,059
	232,908	(94,493)	**363,454**	(92,710)
Net income (loss)	**649,977**	(484,008)	**974,564**	(562,307)
Items that will be reclassified subsequently to profit or loss				
Foreign exchange (loss) gain on translation to presentation currency	**(338,440)**	926,346	**(641,344)**	942,176
Total comprehensive income	**311,537**	442,338	**333,220**	379,869
Net income (loss) per share – basic and diluted (note 7)	**$0.007**	($0.006)	**$0.011**	($0.006)

The accompanying notes form an integral part of these unaudited condensed interim consolidated financial statements.

Nova Leap Health Corp.

Unaudited Condensed Interim Consolidated Statements of Changes in Shareholders' Equity

(United States dollars)

	Common shares	Share capital $	Contributed surplus $	Accumulated other comprehensive loss $	Deficit $	Total shareholders' equity $
Balance at January 1, 2026	**87,314,252**	**19,104,212**	**2,416,565**	**(1,419,901)**	**(1,058,859)**	**19,042,017**
Stock-based compensation	**-**	**-**	**42,653**	**-**	**-**	**42,653**
Net income for the period	**-**	**-**	**-**	**-**	**974,564**	**974,564**
Loss on foreign currency translation	**-**	**-**	**-**	**(641,344)**	**-**	**(641,344)**
Balance at June 30, 2026	**87,314,252**	**19,104,212**	**2,459,218**	**(2,061,245)**	**(84,295)**	**19,417,890**
Balance at January 1, 2025	87,314,252	19,104,212	2,309,419	(2,295,700)	(868,995)	18,248,936
Stock-based compensation	-	-	35,733	-	-	35,733
Net loss for the period	-	-	-	-	(562,307)	(562,307)
Gain on foreign currency translation	-	-	-	942,176	-	942,176
Balance at June 30, 2025	87,314,252	19,104,212	2,345,152	(1,353,524)	(1,431,302)	18,664,538

The accompanying notes form an integral part of these unaudited condensed interim consolidated financial statements.

Nova Leap Health Corp.

Unaudited Condensed Interim Consolidated Statements of Cash Flows

(United States dollars)

For the	Three months ended June 30		Six months ended June 30	
	2026	**2025**	**2026**	**2025**
	$	**$**	**$**	**$**
Cash provided by (used in)				
Operating activities				
Net income (loss) for the period	**649,977**	(484,008)	**974,564**	(562,307)
Adjustments for items not affecting cash:				
Amortization and depreciation	**178,763**	208,890	**327,582**	405,643
Deferred income tax expense (recovery)	**152,542**	(85,368)	**223,693**	(130,769)
Stock-based compensation	**21,406**	18,578	**42,653**	35,733
Finance expense	**93,453**	94,127	**172,584**	175,229
Unrealized foreign exchange (gain) loss	**(242,330)**	786,991	**(482,208)**	800,461
Net change in non-cash operating working capital (note 8)	**53,733**	72,722	**44,882**	84,700
Cash provided by operating activities	**907,544**	611,932	**1,303,750**	808,690
Investing activities				
Acquisition of businesses, net of cash acquired (note 3)	**(2,318,001)**	(279,919)	**(2,318,001)**	(1,242,934)
Cash used in investing activities	**(2,318,001)**	(279,919)	**(2,318,001)**	(1,242,934)
Financing activities				
Proceeds from demand loan, net of debt issue costs (note 4)	**1,585,728**	-	**1,585,728**	937,811
Repayment of demand loans and transaction costs (note 4)	**(163,721)**	(123,850)	**(302,933)**	(229,405)
Interest payments on demand loans (note 4)	**(36,104)**	(43,850)	**(73,907)**	(86,582)
Repayment of promissory notes and interest (note 5)	**(26,250)**	(27,500)	**(26,250)**	(27,500)
Repayment of lease liability and interest	**(105,893)**	(98,972)	**(210,463)**	(192,205)
Cash provided by (used in) financing activities	**1,253,760**	(294,172)	**972,175**	402,119
Effect of foreign exchange rate change on cash and cash equivalents	**(6,770)**	22,328	**(9,214)**	22,642
(Decrease) increase in cash and cash equivalents for the period	**(163,467)**	60,169	**(51,290)**	(9,483)
Cash and cash equivalents - beginning of period	**1,605,102**	1,333,115	**1,492,925**	1,402,767
Cash and cash equivalents - end of period	**1,441,635**	1,393,284	**1,441,635**	1,393,284

1. Nature of operations

Nova Leap Health Corp. (the “Corporation”) is the parent company and was incorporated under the Canada Business Corporations Act on November 16, 2015. The principal activities of the Corporation and its subsidiaries (the “Group”) are to provide healthcare services focused on home-based and community-based care. The Group is currently providing services in the United States as well as in Nova Scotia, Canada. The Corporation is a public corporation whose shares are listed and posted for trading on the TSX Venture Exchange under the symbol NLH and the over-the-counter market (OTCQX) in the United States under the symbol NVLPF.

These Unaudited Condensed Interim Consolidated Financial Statements include the accounts of the Corporation and its United States (“US”) and Canadian subsidiaries and are presented in United States dollars (“USD”) which is the functional currency of the majority of the Group’s business operations. The registered head office of the Corporation is located at 7071 Bayers Road, Suite 3006, Halifax, NS Canada B3L 2C2.

The Unaudited Condensed Interim Consolidated Financial Statements were approved by the Board of Directors on August 7, 2026.

2. Material accounting policies

Statement of compliance
These Unaudited Condensed Interim Consolidated Financial Statements are prepared in accordance with IAS 34, Interim Financial Reporting as issued by the International Accounting Standards Board (‘‘IASB’’). These Unaudited Condensed Interim Consolidated Financial Statements were prepared using the same accounting policies and methods of computation and are subject to the same use of estimates and judgments as the Corporation’s Audited Consolidated Financial Statements for the year ended December 31, 2025. These Unaudited Condensed Interim Consolidated Financial Statements do not include all disclosures required by IFRS Accounting Standards as issued by the International Accounting Standards Board (“IFRS Accounting Standards”) for annual consolidated financial statements and accordingly should be read in conjunction with the Corporation’s Audited Consolidated Financial Statements for the year ended December 31, 2025, prepared in accordance with IFRS Accounting Standards.

3. Business acquisitions

On May 1, 2026, the Corporation acquired 100% of the shares of a home care services business in Nova Scotia, Canada, which the Corporation determined met the definition of a business in accordance with IFRS 3 Business Combinations (“IFRS 3”).

Details of the acquisition, including the preliminary allocation of purchase price, are as follows:

Acquisition date	Nova Scotia May 1, 2026
	$
Total purchase price	**2,642,545**
Fair value of consideration transferred	
Cash	2,357,101
Promissory Note	204,489
Working capital adjustment	80,955
Total	**2,642,545**

(United States dollars)

3. Business acquisitions (continued)

Recognized amounts of identifiable net assets	
Cash and cash equivalents	39,100
Other working capital	41,855
Property and equipment	15,448
Intangible assets - customer lists	383,029
Intangible assets - non-compete agreements	235,710
Deferred income tax liability	(183,914)
Goodwill	2,111,317
Total	**2,642,545**
Acquisition costs	**24,140**

Goodwill
Goodwill is primarily related to growth expectations, expected future profitability and the assembled workforce.

Business acquisitions completed in 2025

During the year ended December 31, 2025, the Corporation completed two business acquisitions. The combined total purchase price was $1,280,023 and resulted in Intangible assets of $358,879 and Goodwill of $943,075 recognized by the Corporation.

4. Demand loans

The changes in the demand loans for the period are as follows:

	June 30, 2026 $	December 31, 2025 $
At amortized cost:		
Balance, beginning of period	**1,786,887**	1,211,204
Proceeds from issuance of demand loan	**1,620,507**	963,014
Debt issue costs	**(34,779)**	(25,203)
Guarantee insurance costs	**(17,043)**	(27,506)
Effective interest	**126,272**	237,843
Interest payments	**(73,907)**	(165,660)
Principal repayment in cash	**(285,890)**	(444,701)
Foreign exchange (gain) loss	**(80,826)**	37,896
Balance, end of period	**3,041,221**	1,786,887
Fair value	**3,107,025**	1,853,134

During 2024, the Corporation entered into an agreement to amend its existing credit agreement with its primary lender. The amended credit facilities provided the Corporation with access to non-revolving demand loans of CAD$1,380,000 and $6,007,000 to assist with financing business acquisitions.

During the three months ended June 30, 2026, the Corporation received proceeds of USD$1,620,507 (CAD$2,200,000) from the issuance of a non-revolving demand loan to finance the business acquisition completed during the period. Following the funding of the business acquisition completed, the Corporation had access to $3,050,000 of additional acquisition financing under its credit facilities, subject to lender approval and satisfaction of the terms of the credit agreement.

During the three months ended June 30, 2026, the Corporation entered into agreements with its lender to convert the interest rates on its outstanding non-revolving demand loans from floating rates to fixed rates. The two previously outstanding demand loans were converted to fixed interest rates of 5.44% on the Canadian dollar loan and 6.33% on the U.S. dollar loan for terms of 36 months. The demand loan issued during the period was converted to a fixed interest rate of 5.06% for a term of 12 months. Prior to conversion to the fixed rate loans, interest was paid at CAD Prime rate plus 1.5% and US base rate plus 1.5%.

(United States dollars)

4. Demand loans (continued)

The non-revolving loans outstanding are repayable on demand. Provided that no demand is made by the lender, the loans are repayable through blended monthly principal and interest payments based on a maximum amortization period of 60 months. Upon expiry of the applicable fixed-rate terms, the loans will revert to the applicable interest rates under the Corporation's credit agreement unless otherwise amended.

The Corporation also has access to a $1,055,595 (CAD$1,500,000) revolving operating facility for working capital purposes from a Schedule 1 Canadian bank. The interest rate is the CAD prime rate plus 1.5%. Interest is calculated monthly in arrears, and payable on the last day of each month. The facility is repayable on demand. There was no outstanding balance on this facility as at June 30, 2026 or December 31, 2025.

The revolving operating facility and demand loans are secured through a registered General Security Agreement and joint and several unlimited guarantees from the Corporation's US and Canadian subsidiaries.

5. Promissory notes

The changes in the promissory notes for the period are as follows:

	June 30, 2026 $	December 31, 2025 $
Balance, beginning of period	**220,147**	330,196
Issuance of promissory notes for acquisition of business (note 3)	**204,489**	-
Effective interest	**12,568**	33,718
Repayments	**(26,250)**	(143,767)
Foreign exchange gain	**(9,264)**	-
Balance, end of period	**401,690**	220,147
Current portion	**173,845**	125,899
Non-current portion	**227,845**	94,248
Balance, end of period	**401,690**	220,147
Fair value	**400,003**	228,072

The promissory notes were all initially recorded at fair value using market interest rate of 5.95 - 9.75% and subsequently measured at amortized cost using the effective interest rate method.

The promissory notes are subject to a Guaranty Agreement from the Corporation and are subordinated to the demand loans (note 4).

6. Share capital

a. Authorized:
Unlimited number of common shares, without nominal or par value.

b. Issued and outstanding:

	June 30, 2026		December 31, 2025	
	Number of Shares	Cost $	Number of Shares	Cost $
Balance, beginning and end of period	**87,314,252**	**19,104,212**	87,314,252	19,104,212

7. Earnings per share

Basic earnings per share is calculated based on the weighted average number of shares outstanding during the period. Diluted earnings per share assumes that stock options and DSUs have been exercised or settled on the later of the beginning of the period and the date granted. For the three and six months ended June 30, 2026, 4,375,000 and 7,275,000 stock options and DSUs were excluded from the computation of diluted earnings per share because their effect would have been anti-dilutive.

(United States dollars)

7. Earnings per share (continued)

For the three and six months ended June 30, 2025, all stock options and DSUs were excluded from the computation of diluted income (loss) per share because their effect would have been anti-dilutive.

The following table summarizes the basic and diluted weighted average number of shares:

	Three months ended June 30		Six months ended June 30	
	2026	**2025**	**2026**	**2025**
Weighted average number of shares used in basic earnings per share	**87,314,252**	87,314,252	**87,314,252**	87,314,252
Shares deemed to be issued for no consideration in respect of share-based payments	**952,306**	-	**758,628**	-
Weighted average number of shares used in diluted earnings per share	**88,266,558**	87,314,252	**88,072,880**	87,314,252

8. Supplemental cash flow information

The change in the non-cash operating working capital is as follows:

	Three months ended June 30		Six months ended June 30	
	2026	**2025**	**2026**	**2025**
	$	**$**	**$**	**$**
Accounts receivable	**(120,135)**	78,275	**(107,057)**	47,587
Prepaid expenses	**(107,606)**	(17,505)	**(149,492)**	(7,451)
Accounts payable and accrued liabilities	**295,938**	8,761	**296,565**	48,847
Client deposits payable	**(14,464)**	3,191	**4,866**	(4,283)
	53,733	72,722	**44,882**	84,700
Supplemental information:				
Interest paid	**45,679**	59,493	**96,327**	117,883
Income taxes paid	**147,547**	52,851	**186,019**	60,232

9. Related party transactions

Transactions with related parties are in the normal course of operations and are measured at the exchange amount, which is the amount agreed to by the parties. Related parties include members of the Board of Directors, as well as the Chief Executive Officer and the Chief Financial Officer.

Corporate and administrative expenses include the following related party remuneration expenses:

	Three months ended June 30		Six months ended June 30	
	2026	**2025**	**2026**	**2025**
	$	**$**	**$**	**$**
Management compensation	**140,790**	108,547	**234,761**	230,647
Directors' compensation	**34,687**	34,677	**69,692**	68,120
Stock-based compensation	**19,085**	15,481	**37,757**	29,951
	194,562	158,705	**342,210**	328,718

As at June 30, 2026, there was $64,849 included in accounts payable and accrued liabilities for amounts owed to officers of the Corporation for compensation and expense reimbursements (December 31, 2025 – $83,619) and $10,556 for amounts due to directors for directors' fees (December 31, 2025 – $10,944).

(United States dollars)

9. Related party transactions (continued)

On January 20, 2025, the Corporation acquired 100% of the shares of an affiliated Nova Scotia based home care business. The acquisition was a non-arm's length transaction as the shares were previously controlled by the Chief Executive Officer and a shareholder holding more than 10% of the outstanding shares of the Corporation.

10. Financial instruments

The Group's risk management is coordinated at its Head Office, in close cooperation with the Board of Directors, and focuses on actively securing the Group's short to medium-term cash flows by maximizing cash flow from operations. The Group is exposed to various risks in relation to financial instruments. The main types of risks are credit risk, liquidity risk and market risk. The Group is exposed to the same risks in the current year as it was exposed to in the prior year. The most significant financial risks to which the Group is exposed are described below.

Credit risk

Credit risk is the risk that a counterparty fails to discharge an obligation to the Group. The Group is exposed to this risk for various financial instruments, for example by granting receivables to customers and placing deposits.

The Group's maximum exposure to credit risk is limited to the carrying amount of financial assets recognized at the end of the reporting period, as summarized below:

Classes of financial assets – carrying amounts	June 30, 2026 $	December 31, 2025 $
Cash and cash equivalents	**1,441,635**	1,492,925
Accounts receivable	**2,011,357**	1,837,001
	3,452,992	3,329,926

Credit risk management
The credit risk is managed on a group basis based on the Group's credit risk management policies and procedures. The credit risk in respect of cash balances held with banks is managed by only using major reputable financial institutions.

The Group does not specifically assess the credit quality of clients based on a credit rating but through an informal process while onboarding for service. Invoice terms are generally payable within thirty days. The ongoing credit risk is managed through regular review of the aging analysis.

At certain locations, clients are required to pay an upfront deposit, mitigating the credit risk. As at June 30, 2026, the Group had $42,984 collected for client deposits (December 31, 2025 - $38,118), representing approximately 2.1% of outstanding accounts receivable, billed and accrued (December 31, 2025 – 2.1%).

Liquidity risk

Liquidity risk is the risk that the Group might be unable to meet its obligations. The Group manages its liquidity needs by monitoring scheduled debt servicing payments for long-term financial liabilities as well as forecasting cash inflows and outflows due in day-to-day business. The data used for analysing these cash flows is consistent with that used in the contractual maturity analysis below.

Liquidity needs are monitored in various time bands, on a day-to-day and week-to-week basis, as well as on the basis of a rolling 30-day projection. Long-term liquidity needs for a quarterly outlook period are identified monthly. Net cash requirements are compared to available cash balances and available borrowing facilities in order to determine headroom or shortfalls. This analysis shows that available borrowing facilities and available cash are expected to be sufficient for the next twelve months.

The Group considers expected cash flows from financial assets in assessing and managing liquidity risk, in particular its cash resources and accounts receivable. The Group's existing cash resources and accounts receivable, in addition to the current unused balance of the revolving operating facility and cash flow projections, are expected to be sufficient to meet current contractual cash outflow requirements. Cash flows from accounts and other receivables are all contractually due within 30 days.

10. Financial instruments (continued)

The Group's financial liabilities have contractual maturities (including interest payments where applicable) as summarized below. Maturities on demand loans, principal and interest are based on monthly repayment terms of the Corporation's credit facility and assume the lender does not exercise its contractual demand rights. As the loans are repayable on demand, the lender could require repayment earlier than the scheduled amounts presented below.

As at June 30, 2026	**< 1 year** **$**	**1-2 years** **$**	**3-5 years** **$**	**> 5 years** **$**
Accounts payable and accrued liabilities	1,881,041	-	-	-
Client deposits	42,984	-	-	-
Promissory notes, principal and interest	187,662	183,056	71,780	-
Demand loans, principal and interest	862,347	862,347	1,755,002	-
Lease liability, principal and interest	429,803	300,324	350,930	41,949
Total	3,403,837	1,345,727	2,177,712	41,949

As at December 31, 2025	**< 1 year** **$**	**1-2 years** **$**	**3-5 years** **$**	**> 5 years** **$**
Accounts payable and accrued liabilities	1,469,705	-	-	-
Client deposits	38,118	-	-	-
Promissory notes, principal and interest	136,116	113,067	-	-
Demand loans, principal and interest	587,650	552,638	995,173	-
Lease liability, principal and interest	357,489	279,235	316,738	80,770
Total	2,589,078	944,940	1,311,911	80,770

Market risk

The Group is exposed to market risk through its use of financial instruments and specifically to currency risk and interest rate risk, which result from both its operating and financing activities.

Foreign currency sensitivity
The Group's operations are predominantly carried out in United States dollars (USD). Exposure to currency exchange rates arises from the fact that the Group's equity offerings have been denominated in Canadian dollars (CAD) and will be denominated in CAD for the foreseeable future as the Corporation's shares are listed on a Canadian stock exchange and the Group has operations in Canada that transact in Canadian dollars.

Additionally, the Group finances operations through intercompany loans issued by the parent company in CAD to the US subsidiaries. Translation of these CAD items to USD within the USD functional currency operational entities, creates exposure to foreign exchange ("FX") risk in the determination of net income (loss). The translation of the CAD functional currency entities to the USD presentation currency creates exposure to FX risk through other comprehensive income. The Group does not hedge its net investment in its Canadian entities and the related foreign currency translation of their earnings, which flow through other comprehensive income (loss).

The Group's exposure to the Canadian dollar ("CAD") currency risk was as follows:

	June 30, 2026 **CAD$**	**December 31, 2025** **CAD$**
Cash and cash equivalents	**992,365**	817,447
Accounts receivable	**877,085**	720,324
Accounts payable & accrued liabilities	**(1,037,204)**	(820,061)
Lease liability	**(590,290)**	(681,787)
Promissory note	**(280,374)**	-
Demand loans	**(3,081,457)**	(1,107,148)
	(3,119,875)	(1,071,225)

(United States dollars)

10. Financial instruments (continued)

A change of 5.0% in the Canadian dollar exchange rate at June 30, 2026 would affect net income (loss) and deficit by approximately $105,000 (June 30, 2025 - $55,000).

Interest rate sensitivity
As at June 30, 2026, the Corporation's outstanding borrowings bear fixed interest rates for their respective contractual fixed-rate terms. Accordingly, a 1% increase or decrease in market interest rates would have no impact on annual net income, comprehensive income or deficit (June 30, 2025 – approximately $17,000).

Fair value

The carrying amounts of financial assets and financial liabilities measured at amortized cost approximate their fair value due to their short-term nature, except for the demand loans and promissory notes, the fair values of which are disclosed in notes 4 and 5.

11. Segment reporting

Management identifies the Group's reportable segments as Canadian operations and US operations. All businesses provide home care services to clients. These operating segments are monitored by the Group's Chief Executive Officer and strategic decisions are made based on segment operating results. Group Head Office provides management oversight and expertise including merger and acquisitions services.

Segment information for the reporting period is as follows:

	For the three months ended June 30, 2026				
	US $	Canada $	Total Reportable Segments $	Group Head Office $	Total $
Segment revenues	**6,888,135**	**2,505,167**	**9,393,302**	**-**	**9,393,302**
Cost of services	4,019,796	1,587,044	5,606,840	-	5,606,840
Gross margin	**2,868,339**	**918,123**	**3,786,462**	**-**	**3,786,462**
Corporate & administrative [(i)]	1,877,006	517,375	2,394,381	437,245	2,831,626
Amortization and depreciation	90,692	71,994	162,686	16,077	178,763
Stock-based compensation	1,482	1,114	2,596	18,810	21,406
Segment operating income (loss)	**899,159**	**327,640**	**1,226,799**	**(472,132)**	**754,667**
Segment assets	**17,995,957**	**7,042,644**	**25,038,601**	**757,376**	**25,795,977**

	For the three months ended June 30, 2025				
	US $	Canada $	Total Reportable Segments $	Group Head Office $	Total $
Segment revenues	**6,327,571**	**1,693,501**	**8,021,072**	**-**	**8,021,072**
Cost of services	3,714,838	1,082,362	4,797,200	-	4,797,200
Gross margin	**2,612,733**	**611,139**	**3,223,872**	**-**	**3,223,872**
Corporate & administrative [(i)]	1,895,990	406,122	2,302,112	343,853	2,645,965
Amortization and depreciation	141,797	51,020	192,817	16,073	208,890
Stock-based compensation	1,797	1,114	2,911	15,667	18,578
Segment operating income (loss)	**573,149**	**152,883**	**726,032**	**(375,593)**	**350,439**
Segment assets	**18,309,178**	**4,524,780**	**22,833,958**	**757,561**	**23,591,519**

(United States dollars)

11. Segment Reporting (continued)

	For the six months ended June 30, 2026				
	US **$**	**Canada** **$**	**Total Reportable Segments** **$**	**Group Head Office** **$**	**Total** **$**
Segment revenues	**12,895,913**	**4,349,283**	**17,245,196**	**-**	**17,245,196**
Cost of services	7,571,994	2,754,490	10,326,484	-	10,326,484
Gross margin	**5,323,919**	**1,594,793**	**6,918,712**	**-**	**6,918,712**
Corporate & administrative *(i)*	3,789,996	943,742	4,733,738	768,830	5,502,568
Amortization and depreciation	175,916	119,364	295,280	32,302	327,582
Stock-based compensation	2,953	2,220	5,173	37,480	42,653
Segment operating income (loss)	**1,355,054**	**529,467**	**1,884,521**	**(838,612)**	**1,045,909**
Segment assets	**17,995,957**	**7,042,644**	**25,038,601**	**757,376**	**25,795,977**

	For the six months ended June 30, 2025				
	US **$**	**Canada** **$**	**Total Reportable Segments** **$**	**Group Head Office** **$**	**Total** **$**
Segment revenues	**12,106,134**	**3,008,135**	**15,114,269**	**427**	**15,114,696**
Cost of services	7,191,193	1,932,901	9,124,094	-	9,124,094
Gross margin	**4,914,941**	**1,075,234**	**5,990,175**	**427**	**5,990,602**
Corporate & administrative *(i)*	3,789,177	677,618	4,466,795	656,840	5,123,635
Amortization and depreciation	287,622	86,582	374,204	31,439	405,643
Stock-based compensation	3,455	2,147	5,602	30,131	35,733
Segment operating income (loss)	**834,687**	**308,887**	**1,143,574**	**(717,983)**	**425,591**
Segment assets	**18,309,178**	**4,524,780**	**22,833,958**	**757,561**	**23,591,519**

i) Corporate & administrative includes Head office and operations management expenses and general & administrative expenses.

The Group's revenues from external customers and its non-current assets are all attributable to the U.S. and Canada segments. Revenues from external customers are identified based on the client's geographical location. Non-current assets are allocated based on their physical location.